选择性雌激素受体降解剂(S)-8-(4-(1-(3-氟丙基)吡咯烷-3-基)氧基)苯基)-7-(4-羟基苯基)-5,6-二氢萘-2-醇的汇聚合成

doi:10.6023/cjoc202403009

有机化学 ›› 2024, Vol. 44 ›› Issue (11): 3550-3555.DOI: 10.6023/cjoc202403009 上一篇下一篇

研究简报

选择性雌激素受体降解剂(S)-8-(4-(1-(3-氟丙基)吡咯烷-3-基)氧基)苯基)-7-(4-羟基苯基)-5,6-二氢萘-2-醇的汇聚合成

陈盼盼^a, 冯晓伟^a, 陆智彭^b, 厉廷有^a^,^b^,^*()

a 南京医科大学药学院核药学系南京 211166
b 南京医科大学药学院药物化学系南京 211166

收稿日期:2024-03-06 修回日期:2024-05-21 发布日期:2024-06-24
基金资助:
南京医科大学科技发展基金(NMUB20210013); 南京医科大学内涵建设重点项目; 中国博士后科学基金(2022M711419); 及江苏省自然科学基金(BK20231266)

Convergent Strategy to Synthesize (S)-8-(4-((1-(3-Fluoropropyl)-pyrrolidin-3-yl)oxy)phenyl)-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol as a Selective Estrogen Receptor Degrader

Panpan Chen^a, Xiaowei Feng^a, Zhipeng Lu^b, Tingyou Li^a^,^b,*()

a Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing 211166
b Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University, Nanjing 211166

Received:2024-03-06 Revised:2024-05-21 Published:2024-06-24
Contact: *E-mail:l_tingyou@njmu.edu.cn
Supported by:
Science and Technology Development Foundation of Nanjing Medical University(NMUB20210013); Key Project of Connotation Construction of Nanjing Medical University; China Postdoctoral Science Foundation(2022M711419); Natural Science Foundation of Jiangsu Province(BK20231266)

文章分享

1. cjoc202403009辅助材料.pdf(1528KB)

摘要/Abstract

报道了一种更为可行的选择性雌激素受体降解剂(S)-8-(4-(1-(3-氟丙基)吡咯烷-3-基)氧)苯基)-7-(4-羟基苯基)-5,6-二氢萘-2-醇的汇聚合成策略, 其合成过程简洁, 不存在区域选择性难题.

关键词: 乳腺癌, 选择性雌激素受体降解剂, (S)-8-(4-(1-(3-氟丙基)吡咯烷-3-基)氧基)苯基)-7-(4-羟基苯基)-5,6-二氢萘- 2-醇, 合成改进

A more feasibly convergent synthesis of selective estrogen receptor degrading agent (S)-8-(4-((1-(3-fluoropropyl)- pyrrolidin-3-yl)oxy)phenyl)-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol was reported, featured with concise work up and absence of regioselectivity dilemma.

Key words: breast cancer, selective estrogen receptor degrading agent, (S)-8-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)- phenyl)-7-(4 -hydroxyphenyl)-5,6-dihydronaphthalen-2-ol, improvement of synthesis

引用此文

陈盼盼, 冯晓伟, 陆智彭, 厉廷有. 选择性雌激素受体降解剂(S)-8-(4-(1-(3-氟丙基)吡咯烷-3-基)氧基)苯基)-7-(4-羟基苯基)-5,6-二氢萘-2-醇的汇聚合成[J]. 有机化学, 2024, 44(11): 3550-3555.

Panpan Chen, Xiaowei Feng, Zhipeng Lu, Tingyou Li. Convergent Strategy to Synthesize (S)-8-(4-((1-(3-Fluoropropyl)-pyrrolidin-3-yl)oxy)phenyl)-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol as a Selective Estrogen Receptor Degrader[J]. Chinese Journal of Organic Chemistry, 2024, 44(11): 3550-3555.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

图/表 2

Scheme 1. Synthetic route of compound 1 as reported in the original literature, along with its potential by-products Reagents and conditions: (a) KHMDS, PhN(SO2CF3)2, THF, －50 °C to r.t., 96%; (b) (4-hydroxyphenyl) boronic acid, PdCl2(dppf), Cs2CO3, dioxane, H2O, r.t., 70%; (c) pyridinium tribromide, THF, r.t., 79%; (d) (4-methoxyphenyl)boronic acid, PdCl2(dppf), Cs2CO3, dioxane, H2O, 70 °C, 55%; (e) tert-butyl (R)-3-hydroxypyrrolidine-1-carboxylate, (E)-N1,N1,N2,N2-tetramethyldiazene-1,2-dicarboxamide, PPh3, THF, rt, 75%; (f) 4 mol/L HCl, dioxane, MeOH, r.t., 93%; (g) BF3?Me2S, DCM, r.t., 71%; (h) Iodoalkyl, K2CO3, DMF, 70 °C, 40%.

Scheme 2. Convergent synthetic approach for compound 1 Reagents and conditions: (a) AlCl3, toluene, reflux, 90%; (b) di-tert-butyl dicarbonate, 4-dimethylaminopyridine, acetone, 40 ℃, 95%; (c) KHMDS, PhN(SO2CF3)2, THF, －50 ℃ to r.t., 86%; (d) tert-butyl (R)-3-hydroxypyrrolidine-1-carboxylate, 1,1'-azobis(N,N-dimethylformamide), PPh3, THF, 0 ℃ to r.t., 86%; (e) HCl in ethyl acetate, r.t.; (f) 1-fluoro-3-iodopropane, K2CO3, DMF, 80 ℃, 42%; (g) PdCl2(dppf), Cs2CO3, dioxane, 100 ℃, 75%; (h) pyridinium tribromide, THF, r.t.; (i) 4-hydroxyphenylboronic acid, PdCl2(dppf), Cs2CO3, dioxane, H2O, 100 ℃, 52% (two-step yield); (j) trifluoroacetic acid, DCM, r.t., 82%.

参考文献 10

[1]	Sung H.; Ferlay J.; Siegel R.; Laversanne M.; Soerjomataram I.; Jemal A.; Freddie Bray F. Ca-Cancer J. Clin. 2021, 71, 209.
[2]	Tang J.; Wu Z.; Tian Z.; Chen W.; Wu G. Cell Death Discovery 2021, 12, 534.
[3]	Huang B.; Omoto Y.; Iwase H.; Yamashita H.; Toyama T.; Coombes R.; Filipovic A.; Warner M.; Gustafsson J. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 1933.
[4]	Burstein H. N. Engl. J. Med. 2020, 383, 2557.
[5]	Jin M.; Yang L.; Jeong K. Theranostics 2022, 12, 5761.
[6]	Ma C.; Reinert T.; Chmielewska I.; Ellis M. Nat. Rev. Cancer 2015, 15, 261.
[7]	Osborne C.; Pippen J.; Jones S.; Parker L.; Ellis M.; Come S.; Gertler S.; May J.; Burton G.; Dimery I.; Webster A.; Morris C.; Elledge R.; Buzdar A. J. Clin. Oncol. 2002, 20, 3386. doi: 10.1200/JCO.2002.10.058 pmid: 12177098
[8]	Wakeling A.; Dukes M.; Bowler J. Cancer. Res 1991, 51, 3867. pmid: 1855205
[9]	Kruchten M.; de Vries E.; Glaudemans A.; van Lanschot M.; van Faassen M.; Kema I.; Brown M.; Schröder C.; de Vries E.; Hospers G. Cancer Discovery 2015, 5, 72. doi: 10.1158/2159-8290.CD-14-0697 pmid: 25380844
[10]	El-Ahmad Y.; Tabart M.; Halley F.; Certal V.; Thompson F.; Filoche-Rommé B.; Gruss-Leleu F.; Muller C.; Brollo M.; Fabien L.; Loyau V.; Bertin L.; Richepin P.; Pilorge F.; Desmazeau P.; Girardet C.; Beccari S.; Louboutin A.; Lebourg G.; Le-Roux J.; Terrier C.; Vallée F.; Steier V.; Mathieu M.; Rak A.; Abecassis P.; Vicat P.; Benard T.; Bouaboula M.; Sun F.; Shomali M.; Hebert A.; Levit M.; Cheng H.; Courjaud A.; Ginesty C.; Perrault C.; Garcia-Echeverria C.; McCort G.; Schio L. J. Med. Chem. 2020, 63, 512. doi: 10.1021/acs.jmedchem.9b01293 pmid: 31721572

选择性雌激素受体降解剂(S)-8-(4-(1-(3-氟丙基)吡咯烷-3-基)氧基)苯基)-7-(4-羟基苯基)-5,6-二氢萘-2-醇的汇聚合成

Convergent Strategy to Synthesize (S)-8-(4-((1-(3-Fluoropropyl)-pyrrolidin-3-yl)oxy)phenyl)-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol as a Selective Estrogen Receptor Degrader

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用此文

分享此文

图/表 2

参考文献 10

相关文章 3

编辑推荐

相关统计

本文评价

[1]	许旭升, 刘志千, 邵文浩, 叶霁, 孙青龑, 何薇薇, 张卫东. 氯化两面针碱合成方法的改进[J]. 有机化学, 2015, 35(6): 1353-1356.
[2]	杨光, 朱华, 沈玉梅. 新型聚乙二醇(PEG)-Cyclofenil雌激素受体分子β探针的合成[J]. 有机化学, 2011, 31(05): 715-723.
[3]	朱华a,b 黄立梁a,b 张春春a,b 许嘉a 沈玉梅*,a. 含Cyclofenil结构单元的三羰基铼配合物的合成[J]. 有机化学, 2009, 29(9): 1450-1456.